| Subject: | FDA Issues Notice on Reminyl/Amaryl Sound Alike Dispensing and Administering Errors |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 1 Nov 2004 - 10:00 am |
| The FDA has reported that the medication Reminyl (galantamine hydrobromide) which is a reversible, competitive acetylcholinesterase inhibitor, prescribed for the treatment of Alzheimer's related dementia, has been prescribed with the medication Amaryl (glimepiride) being dispensed and administered in error. Amaryl is an oral blood glucose lowering drug in the sulfonylurea class. The FDA reports that it appears the error is due to the sound alike nature of these two drugs, and that there has... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
Related MCN Products:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
